International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 2 , Pages 321-328 , 1 June 2010

A Multicenter Retrospective Analysis of Survival Outcome Following Postoperative Chemoradiotherapy in Non–Small-Cell Lung Cancer Patients With N2 Nodal Disease

  • Bingwen Zou, M.D.

      Affiliations

    • Department of Thoracic Oncology, Cancer Center, Huaxi Hospital, Medical School, Sichuan University, Chengdu, China
    • ,
  • Yong Xu, M.D.

      Affiliations

    • Department of Thoracic Oncology, Cancer Center, Huaxi Hospital, Medical School, Sichuan University, Chengdu, China
    • ,
  • Tao Li, M.D.

      Affiliations

    • Department of Radiochemotherapy Oncology, Sichuan Provincial Cancer Hospital, Chengdu, China
    • ,
  • Wenhui Li, M.D.

      Affiliations

    • Department of Radiotherapy Oncology, Yunnan Provincial Cancer Hospital, The Third Affiliated Hospital of Kunming Medical College, Kunming, China
    • ,
  • Bangxian Tang, M.D.

      Affiliations

    • Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
    • ,
  • Lin Zhou, M.D.

      Affiliations

    • Department of Thoracic Oncology, Cancer Center, Huaxi Hospital, Medical School, Sichuan University, Chengdu, China
    • ,
  • Lu Li, M.D.

      Affiliations

    • Department of Thoracic Oncology, Cancer Center, Huaxi Hospital, Medical School, Sichuan University, Chengdu, China
    • ,
  • Yongmei Liu, M.D.

      Affiliations

    • Department of Thoracic Oncology, Cancer Center, Huaxi Hospital, Medical School, Sichuan University, Chengdu, China
    • ,
  • Jiang Zhu, M.D.

      Affiliations

    • Department of Thoracic Oncology, Cancer Center, Huaxi Hospital, Medical School, Sichuan University, Chengdu, China
    • ,
  • Meijuan Huang, M.D.

      Affiliations

    • Department of Thoracic Oncology, Cancer Center, Huaxi Hospital, Medical School, Sichuan University, Chengdu, China
    • ,
  • Jin Wang, M.D.

      Affiliations

    • Department of Thoracic Oncology, Cancer Center, Huaxi Hospital, Medical School, Sichuan University, Chengdu, China
    • ,
  • Li Ren, M.D.

      Affiliations

    • Department of Thoracic Oncology, Cancer Center, Huaxi Hospital, Medical School, Sichuan University, Chengdu, China
    • ,
  • Youlin Gong, M.D.

      Affiliations

    • Department of Thoracic Oncology, Cancer Center, Huaxi Hospital, Medical School, Sichuan University, Chengdu, China
    • ,
  • Guowei Che, M.D.

      Affiliations

    • Department of Thoracic Surgery, Huaxi Hospital, Medical School, Sichuan University, Chengdu, China
    • ,
  • Lunxu Liu, M.D.

      Affiliations

    • Department of Thoracic Surgery, Huaxi Hospital, Medical School, Sichuan University, Chengdu, China
    • ,
  • Mei Hou, M.D.

      Affiliations

    • Department of Thoracic Oncology, Cancer Center, Huaxi Hospital, Medical School, Sichuan University, Chengdu, China
    • ,
  • You Lu, M.D.

      Affiliations

    • Department of Thoracic Oncology, Cancer Center, Huaxi Hospital, Medical School, Sichuan University, Chengdu, China
    • State Key Laboratory of Biotherapy, West China Hospital, Medical School, Sichuan University, Chengdu, China
    • Corresponding Author InformationReprint requests to: You Lu, Department of Thoracic Oncology and State Key Laboratory of Biotherapy, Huaxi Hospital, Medical School, Sichuan University, Chengdu 610041, China. Tel: (+86) 28-85423571; Fax: (+86) 28-85423571

Received 18 February 2009 ,Revised 6 May 2009 ,Accepted 7 May 2009.

References 

  1. Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al. Clinical prognostic factors in surgically treated stage IIIAN2 non small cell lung cancer: Analysis of the literature. Lung Cancer. 1998;19:3–13
  2. Betticher DC, Schmitz SFH, Totsch M, et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: The 5-year follow-up of a phase II study. Br J Cancer. 2006;94:1099–1106
  3. International Adjuvant Lung cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med. 2004;350:351–360
  4. Winton TL, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs observation in resected non-small cell lung cancer Intergroup. N Engl J Med. 2005;352:2589–2597
  5. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised trial. Lancet Oncol. 2006;7:719–727
  6. PORT Meta-analysis Trialists Group: Postoperative radiotherapy in non-small-cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomized controlled trials. Lancet. 1998;352:257–263
  7. Burdett S, Stewart L. Postoperative radiotherapy in non-small cell lung cancer: Update of an individual patient data meta analysis. Lung Cancer. 2005;47:81–83
  8. Lally BE, Zelterman D, Colasanto JM, et al. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the Surveillance, Epidemiology, and End Results Database. J Clin Oncol. 2006;24:2998–3006
  9. Sawyer TE, Bonner JA, Gould PM, et al. Effectiveness of postoperative irradiation in stage IIIA non–small cell lung cancer according to regression tree analyses of recurrence risks. Ann Thorac Surg. 1997;64:1402–1407
  10. Debevec M, Bitenc M, Vidmar S, et al. Postoperative radiotherapy for radically resected N2 non-small-cell lung cancer (NSCLC): Randomized clinical study 1988–1992. Lung Cancer. 1996;14:99–107
  11. Feng QF, Wang M, Wang LJ, et al. A study of postoperative radiotherapy in patients with non-small-cell lung cancer: A randomized trial. Int J Radiat Oncol Biol Phys. 2000;47:925–929
  12. Hsu H-C, Wang C-J, Huang E-Y, et al. Post-operative adjuvant thoracic radiotherapy for patients with completely resected non-small cell lung cancer with nodal involvement: Outcome and prognostic factors. Br J Radiol. 2004;77:43–48
  13. Misthos P, Sepsas E, Athanassiadi K, et al. Skip metastases: Analysis of their clinical significance and prognosis in the IIIA stage of non-small cell lung cancer. Eur J Cardiothorac Surg. 2004;25:502–508
  14. Riquet M, Assouad J, Bagan P, et al. Skip mediastinal lymph node metastasis and lung cancer: A particular N2 subgroup with a better prognosis. Ann Thorac Surg. 2005;79:225–233
  15. Le Péchoux C, De Ruysscher D, Francoise Mornex F, et al. Need for a new trial to evaluate adjuvant postoperative radiotherapy in non–small-cell lung cancer patients with N2 Mediastinal Involvement. J Clin Oncol. 2007;7:e10–e11
  16. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457–481
  17. Lawless JF. Statistical models and methods for lifetime data. New York: Wiley; 1982;
  18. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1711–1717
  19. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187–220
  20. Logan DM, Lochrin CA, Darling G, et al. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small cell lung cancer after complete resection. Cancer Prev Control. 1997;1:366–378
  21. Okawara G, Ung YC, Markman BR, et al. Postoperative radiotherapy in stage II or IIIA completely resected non-small cell lung cancer: A systematic review and practice guideline. Lung Cancer (Amsterdam, Netherlands). 2004;44:1–11
  22. Wang XS, Lu C, Shi Q, et al. Symptom burden and survival outcome: 3 cycles versus 6 cycles of chemotherapy in advanced NSCLC. ASCO Mtg Abstr. Jun 2007;(abstr 25: 17054)
  23. Lung Cancer Study Group . Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med. 1986;315:1377–1381
  24. Mayer R, Smolle-Juettner FM, Szolar D, et al. Postoperative radiotherapy in radically resected non-small cell lung cancer. Chest. 1997;112:954–959
  25. Sawyer TE, Bonner JA, Gould PM, et al. The impact of surgical adjuvant thoracic radiation therapy for patients with non-small cell lung carcinoma with ipsilateral mediastinal lymph node involvement. Cancer. 1997;80:1399–1408
  26. Douillard J-Y, Rosell R, De Lena M, et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: The Adjuvant Navelbine International Trialist Association (ANITA) randomized trial. Int J Radiat Oncol Biol Phys. 2008;72:695–701
  27. Stephens RJ, Girling DJ, Bleehen NM, et al. The role of post-operative radiotherapy in non-small-cell lung cancer: A multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Br J Cancer. 1996;74:632–639
  28. Machtay M, Lee JH, Shrager JB, et al. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. J Clin Oncol. 2001;19:3912–3917
  29. Tanaka F, Yanagihara K, Ohtake Y, et al. Time trends and survival after surgery for p-stage IIIa, pN2 non-small cell lung cancer (NSCLC). Eur J Cardiothorac Surg. 1997;12:372–379

 Bingwen Zou, Yong Xu, Tao Li, Wenhui Li, and Bangxian Tang contributed equally to this work.

 Supported in part by a grant from the Radiation Oncology Program at Huaxi Hospital, Medical School, Sichuan University (No.137060072).

 Conflict of interest: none.

PII: S0360-3016(09)00827-X

doi: 10.1016/j.ijrobp.2009.05.044

International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 2 , Pages 321-328 , 1 June 2010

Article Tools

* Image Usage & Resolution